Optipharm

옵티팜 · 153710

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$49.1M (₩67.8B)

Overview

Optipharm develops and supplies products and services across animal health, including veterinary disease diagnostics, animal medicines, and bacteriophage-based treatments, naturally occurring viruses that target and destroy harmful bacteria without affecting animal cells or beneficial microbes.

Its customers include livestock-related industries and research users who need diagnostic services and tested animal medicines. Listed on KOSDAQ, Korea's tech and small-cap board, the company's animal medicines division is its largest revenue contributor, followed by diagnostics and bacteriophage products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$16.2M

▲ +13.8% YoY

Operating profit · FY2025

−US$1.7M

Loss narrowed

Net income · FY2025

−US$1.8M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$12.6M(₩17.4B)	US$14.2M(₩19.6B)	US$16.2M(₩22.3B)
Operating profit	−US$1.9M(−₩2.6B)	−US$1.8M(−₩2.5B)	−US$1.7M(−₩2.4B)
Net income	−US$1.8M(−₩2.4B)	−US$1.7M(−₩2.4B)	−US$1.8M(−₩2.5B)

Revenue

FY2023US$12.6M
FY2024US$14.2M
FY2025US$16.2M

Operating profit

FY2023−US$1.9M
FY2024−US$1.8M
FY2025−US$1.7M

Net income

FY2023−US$1.8M
FY2024−US$1.7M
FY2025−US$1.8M

Key ratios (FY2025)

ROE

-9.8%

Debt/Eq

60.5%

Op. margin

-10.8%

Net margin

-11.2%

Rev. YoY

▲ +13.8%

Why it matters

Optipharm also produces genetically modified miniature pigs, sourced originally from the Sinclair Research Center in the US, for use in xenotransplantation research, applying gene-editing technologies to improve compatibility with human biology.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?